Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 15/20 | 0.67 |
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.62 |
| ▸ | GHSR | Q92847 | 2/20 | 0.61 |
| ▸ | NPY2R | P49146 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32662800 | 0.95 | KISS1R (0.74) | KISS1RIL23RGHSRNPY2R | |
| SCHEMBL29383648 | 0.95 | KISS1R (0.69) | KISS1RIL23RGHSRNPY2R | |
| SCHEMBL29725112 | 0.91 | KISS1R (0.62) | KISS1RIL23R | |
| SCHEMBL31257039 | 0.90 | IL1RN (0.65) | KISS1RNPY2R | |
| SCHEMBL30757406 | 0.90 | IL1RN (0.63) | KISS1RNPY2R | |
| SCHEMBL30262062 | 0.89 | KISS1R (0.67) | KISS1RIL23RGHSRNPY2R | |
| SCHEMBL30596141 | 0.88 | IL23R (0.69) | KISS1RIL23R | |
| SCHEMBL29834938 | 0.88 | NPY4R (0.65) | KISS1RNPY2R | |
| SCHEMBL29834946 | 0.88 | NPY4R (0.65) | KISS1RNPY2R | |
| SCHEMBL31092866 | 0.88 | IL23R (0.64) | KISS1RIL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015399-A1 | SOLUBLE NPY2 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2026-01-15 | — | — | US | claimed |
| EP-4192853-A1 | SOLUBLE NPY2 RECEPTOR AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2023-06-14 | — | — | EP | claimed |
| CN-116171282-A | Soluble NPY2 receptor agonists | 勃林格殷格翰国际有限公司 | 2023-05-26 | — | — | CN | claimed |
| US-20220041678-A1 | SOLUBLE NPY2 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-10 | — | — | US | claimed |
| WO-2022029231-A1 | SOLUBLE NPY2 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-10 | — | — | WO | claimed |
| US-20260015399-A1 | SOLUBLE NPY2 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2026-01-15 | — | — | US | disclosed |
| US-12391737-B2 | Soluble NPY2 receptor agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-08-19 | — | — | US | disclosed |
| EP-4192853-A1 | SOLUBLE NPY2 RECEPTOR AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2023-06-14 | — | — | EP | disclosed |
| CN-116171282-A | Soluble NPY2 receptor agonists | 勃林格殷格翰国际有限公司 | 2023-05-26 | — | — | CN | disclosed |
| US-20220041678-A1 | SOLUBLE NPY2 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-10 | — | — | US | disclosed |
| WO-2022029231-A1 | SOLUBLE NPY2 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041678-A1 | SOLUBLE NPY2 RECEPTOR AGONISTS | NPY2R, NPY1R, NPY5R | KISS1R 171/4885IL23R 360/4885GHSR 36/4885 |
| US-12391737-B2 | Soluble NPY2 receptor agonists | NPY2R, NPY1R, NPY5R | KISS1R 171/4885IL23R 360/4885GHSR 36/4885 |
| US-20260015399-A1 | SOLUBLE NPY2 RECEPTOR AGONISTS | NPY1R, NPY2R, NPY5R | KISS1R 107/4885IL23R 383/4885GHSR 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.